Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

NRG Oncology: Clinical Trials & FDA Approval Profile

NRG Oncology (Global / Institutional) sponsors 41 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 37 active protocols (18 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.3%
Median Closed Enrollment vs National (145 pts)265 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for NRG Oncology
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)41
Active Pipeline (Recruiting Now)37 (18)
Completed vs Stopped Early1 / 3 (7.3%)
Median Closed Actual Enrollment265 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With NRG Oncology
Hospital Research SiteLocationShared Protocols
University of Oklahoma Health Sciences CenterOklahoma City, OK34
Ohio State University Comprehensive Cancer CenterColumbus, OH32
Carle Cancer CenterUrbana, IL31

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by NRG Oncology
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05646316Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial CancerPhase IIIRECRUITING
NCT07166406Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialPhase IIIRECRUITING
NCT06500481Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase IIIRECRUITING
NCT07452458Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-UnmPhase IIIRECRUITING
NCT07097142Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for BlaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the NRG Oncology Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI